Profile of panobinostat and its potential for treatment in solid tumors: an update.

Content Provider	Europe PMC
Author	Anne, Madhurima Sammartino, Daniel Barginear, Myra F Budman, Daniel
Copyright Year	2013
Abstract	The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer. Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both intravenous and oral formulations across multiple tumor types. Comparable to the other HDACs, panobinostat leads to hyperacetylation of histones and other intracellular proteins, allowing for the expression of otherwise repressed genes, leading to inhibition of cellular proliferation and induction of apoptosis in malignant cells. Panobinostat, analogous to other HDAC inhibitors, also induces apoptosis by directly activating cellular death receptor pathways. Preclinical data suggests that panobinostat has inhibitory activity at nanomolar concentrations and appears to be the most potent clinically available HDAC inhibitor. Here we review the current status of panobinostat and discuss its role in the treatment of solid tumors.
Journal	Oncotargets and Therapy
Volume Number	6
PubMed Central reference number	PMC3833618
PubMed reference number	24265556
e-ISSN	11786930
DOI	10.2147/ott.s30773
Language	English
Publisher	Dove Medical Press
Publisher Date	2013-11-15
Access Restriction	Open
Rights License	The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. © 2013 Anne et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License
Subject Keyword	panobinostat LBH589 histone deacetylase inhibitor solid tumors
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Oncology